AzTrials
AzTrials

Unexplained InfertilityNCT03397693

Assessment of Endometrial Thickness & Subendometrial Perfusion by 3D Power Doppler in Women With Unexplained Infertility and PCOS.

An observational study of Unexplained Infertility and PCOS, run by Assiut University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Evaluation of the endometrial thickness and subendometrial blood perfusion in women with unexplained infertility and PCOS using 3D Power Doppler and uterine artery Doppler in comparison to a control group. Read more about this study

Who is it for?
Any age, women only
How many people
90 participants
Where
1 siteEgypt
Study dates
3 Jan 2018to 20 May 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Women only
  • Child, Adult, Older adult

Study population: 1. unexplained infertility (normal regular menstrual cycles and normal pelvic examination, evidence of ovulation by TV/US and normal mid-luteal serum progesterone, normal semen analysis of the husband according to WHO guidlines2010 (25), and evidence of tubal patency and normal uterine cavity by HSG and/or laparoscopy). 2. Women with PCOS according to Rotterdam ASRM/ESHRE criteria(26) 3. Healthy fertile women (Multipara with last delivery since ≥ 2 years with no history of abortions and not on contraception (hormonal or IUD)).

Who may be able to join

  • • Inclusion criteria of study group (1\&2):
  • Women with primary or secondary infertility for more than 1 year due to unexplained infertility (normal regular menstrual cycles and normal pelvic examination, evidence of ovulation by TV/US and/or normal mid-luteal serum progesterone, normal semen analysis of the husband according to WHO guidlines2010 (25), and evidence of tubal patency and normal uterine cavity by HSG and/or laparoscopy).
  • Women with PCOS according to Rotterdam ASRM/ESHRE criteria(26) • Inclusion criteria for control group (2):
  • <!-- -->
  • Women with no history of menstrual dysfunction or subfertility.
  • Normal regular cycles and normal pelvic examination.
  • Multipara with last delivery since ≥ 2 years with no history of abortions and not on contraception (hormonal or IUD).

Who cannot join

  • • Exclusion criteria of both groups:
  • History of pelvic surgery or pelvic inflammatory disease.
  • Current hormonal contraception.
  • On IUD.
  • History of or clinical features suggesting endometriosis or pelvic pathology like uterine fibroid and ovarian cyst.
  • General medical disorders (e.g. D.M), smoking and lactation.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Department of Obstetrics and Gynecology, School of Medicine, Assiut University

    Asyut, 71500

Other trials in Egypt

About this study

Evaluation of the endometrial thickness and subendometrial blood perfusion in women with unexplained infertility and PCOS using 3D Power Doppler and uterine artery Doppler in comparison to a control group.

Read the detailed description
  • Background Infertility is a frustrating disease that affects many couples around the world. Although there are many etiologies responsible for infertility , there are about 15-30 % of couples who suffer from what is called "Unexplained Infertility". About 25% of infertility is caused by ovulatory disorders. The World Health Organization (WHO) classifies these ovulatory disorders into 3 groups. Group II includes women with hypothalamic-pituitary-ovarian dysfunction (predominately polycystic ovary syndrome (PCOS)) In unexplained infertility, basic investigations that are done first to reveal the cause of infertility reveal normal findings. These basic investigations should provide evidence of ovulation, adequate sperm production and patency of the fallopian tubes.

However, with these routine investigations and even with other more sophisticated investigations it is hard to reveal all possible abnormalities. Therefore, unexplained infertility appears to represent either the lower extreme of the normal distribution of fertility, or it arises from a defect in fecundity that cannot be detected by the routine infertility evaluation. Couples with unexplained infertility suffer from both diminished and delayed fecundity.

Due to absence of specific abnormality in cases with unexplained infertility, the management is usually empiric. Suggested treatment regimens include intrauterine insemination (IUI), ovulation induction with oral or injectable medications, combination of IUI with ovulation induction, and assisted reproductive technologies (ART).

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting young women of reproductive age with the prevalence ranging between 2% to 18% according to different population and diagnostic criteria. It has been suggested that uterine blood flow is impaired in women with PCOS.

Ovulation induction (OI) is by far the most commonly used treatment for women with WHO group II anovulation and clomiphene citrate (CC) has historically been the most used drug In many fertility guidelines, CC is recommended as the first-line treatment for women with group II anovulation or PCOS who wish to conceive. However, other guidelines recommend both CC and letrozole as first-line treatments. It is hypothesized that CC resistance and failure are related to anti-estrogenic effects of CC on the endometrium, cervical mucus, and uterine blood flow.

Each month, the human endometrium undergoes a series of distinct cyclical changes in preparation to receive the developing blastocyst. Such changes necessitate well-controlled dynamic remodeling of the endometrial microvasculature through the processes of angiogenesis and arteriogenesis. Abnormalities of endometrial blood perfusion have been associated with several menstrual disorders including: dysmenorrhea, menorrhagia, intermenstrual bleeding and endometriosis. So, adequate blood perfusion of the endometrium is considered an important factor for what is called "endometrial receptivity". So it is possible that women with unexplained infertility have decreased uterine and endometrial blood perfusion.

Following implantation, there are certain changes that occur in the endometrium and its vasculature. These changes occur simultaneously with the trophoblastic invasion of the spiral arteries, and any kind of abnormalities in these changes has been associated with complications during pregnancy like: recurrent miscarriage, preterm delivery, intrauterine growth restriction and pre-eclampsia. So, the condition of the endometrium is very essential for successful implantation of the gestational sac and one of the most important factors affecting the endometrium is its blood perfusion.

The usual methods of assessment of endometrium like measurement of its thickness and description of its appearance are considered poor indicators of successful implantation and pregnancy.Other tools of investigations include: uterine artery Doppler and pulsed wave Doppler. It was found that information revealed from uterine artery Doppler alone may not represent the perfusion of the endometrium. Also, pulsed wave Doppler is used to examine the smaller downstream radial and spiral arteries and this reveals information from single vessels rather than from the endometrium as a whole. On the other hand, 3D Power Doppler is claimed to be the best investigatory tool for the study of endometrial blood perfusion as it is more sensitive to low flow and thus overcomes the problems of angle dependence and background noise associated with both color and pulsed wave Doppler. In addition, whereas color Doppler provides qualitative information, the 3D Power Doppler signal can be subsequently analyzed to produce quantitative information through one of several computer software packages.

  • Hypothesis: Null hypothesis: There is no difference in endometrial thickness, 2D and 3D Power Doppler indices between normal fertile women, women with unexplained infertility and women with PCOS.

Alternative hypothesis: There is a difference in endometrial thickness, 2D and 3D Power Doppler indices between above-mentioned groups.

Keywords
PCOS, Unexplained infertiltiy, 3D Power Doppler, Endometrial thickness, Subendometrial blood perfusion

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03397693
Study groupRoleWhat they receive
1Women with unexplained infertiltiy with no treatment given
2Women with Poly Cystic Ovary Syndrome (PCOS) who are not being treated with drugs of ovulation induction.
3Control fertile women with no treatment given.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Endometrial thickness

    Thickest part of the endometrium in sagittal plane by transvaginal ultrasound

    Measured: Mid luteal phase defined as (Day 20-24) of the menstrual cycle for each patient

  2. Endometrial and sub-endometrial blood perfusion expressed as VI, FI VFI.

    Endometrial and sub-endometrial blood perfusion by 3D Power Doppler

    Measured: Mid luteal phase defined as (Day 20-24) of the menstrual cycle for each patient

  3. 2D Doppler indices of both uterine arteries

    RI, PI of uterine arteries.

    Measured: Mid luteal phase defined as (Day 20-24) of the menstrual cycle for each patient

Secondary outcomes (3)
  1. Demographic characteristics of included women.

    Demographic characteristics of included women.

    Measured: Mid luteal phase defined as (Day 20-24) of the menstrual cycle for each patient

  2. Endometrial volume

    Using VOCAL software during transvaginal ultrasound examination

    Measured: Mid luteal phase defined as (Day 20-24) of the menstrual cycle for each patient

  3. Uterine volume

    Using VOCAL software during transvaginal ultrasound examination

    Measured: Mid luteal phase defined as (Day 20-24) of the menstrual cycle for each patient

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jan 2018
  2. Study start3 Jan 2018
  3. Primary completion20 Apr 2019
  4. Study completion20 May 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
90 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03397693
Sponsor's protocol ID
17200152
Status last verified
Jun 2019
First submitted
3 Jan 2018
Last updated
2 Jul 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Unexplained Infertility and PCOS, run by Assiut University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Endometrial thickness (time frame: Mid luteal phase defined as (Day 20-24) of the menstrual cycle for each patient). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in